Source link : https://www.newshealth.biz/health-news/ema-approves-factor-viii-deficiency-clotting-drug/
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia A caused by factor VIII deficiency. Patients with this genetic disorder lack a specific clotting protein in the blood that means injured blood vessels cannot heal in the normal […]
Author : News Health
Publish date : 2024-04-26 18:04:11
Copyright for syndicated content belongs to the linked Source.